Remove tag systemic-biologics
article thumbnail

BD partners with Biocorp on connected self-injection devices

pharmaphorum

Medtech giant Beckton Dickinson (BD) has signed a deal with France’s Biocorp to use the latter’s near-field communication (NFC) tags in injectable devices. The Injay tag can confirm a complete injection and transfer that information via an NFC reader to a smartphone or tablet for review by a healthcare professional.

article thumbnail

New purification method could enhance protein drug manufacturing

European Pharmaceutical Review

Producing biologics by isolating proteins Biologics like antibodies and other protein-based drugs are produced by living cells such as yeast in large bioreactors. The authors explained that these are commonly used for tagging proteins for study or attaching protein drugs to drug-delivering nanoparticles.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Upcoming sickle cell gene therapies cost effective at $2 million, says ICER

Pharmaceutical Technology

Although the findings in the report are only preliminary, they shed light at the considerations behind the high price tags of gene therapies. While Vertex and CRISPR submitted the Biologics License Application (BLA) for exa-cel earlier this April, bluebird has yet to do so for lovo-cel. The treatments would have to cost $1.92

article thumbnail

Actualising the power of antibody-drug conjugates as cancer therapeutics

European Pharmaceutical Review

However, the chemistries involved generate heterogeneous mixtures with ADCs having different DARs and clearance properties, and the payload is often prematurely cleaved during systemic circulation. tag ® , inspired by the unique features of microtubule biology and perfectly suited for DAR 2 and DAR 4 ADCs.

article thumbnail

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. Across the world, to varying degrees, the regulations were written in an era of small molecules and biologics. AZ: Allogeneic CAR-T therapies are often described as the future of the field.

article thumbnail

Leading innovators in peptide nano-particle conjugates for the pharmaceutical industry

Pharmaceutical Technology

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

article thumbnail

Advanced therapies and the high-profile pricing dilemma

pharmaphorum

However, R&D efforts into biological medicine have moved into the ascendency in recent times, as the treatments often offer targeted therapy and better outcomes. While this is of tremendous benefit to patients, it provides a headache to the pharma industry and to healthcare systems. However, with a price tag of €1.58

Medicine 123